Self-renewing blood and leukaemia cells need hedgehog
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Attacking an alternative pathway might help defeat disease
Cancer cells often hijack developmental signaling pathways to cause uncontrolled growth. This month in Nature, Tannishtha Reya and her team from Duke University in Durham, North Carolina, show that hedgehog signaling is essential for maintaining chronic myeloid leukaemia and that blocking this pathway with small molecules might be effective in preventing the disease from recurring 1 .
Chronic myeloid leukaemia (CML) occurs after a chromosomal translocation fuses two enzymes that are essential for cell signaling: the BCR serine/threonine kinase and the ABL tyrosine kinase. The primary therapy, Novartis' Gleevec (imatinib), targets part of the ABL kinase. However, the cells that propagate CML appear to be resistant, which would explain why the drug stalls rather than cures the disease. A drug that targeted the propagating cells could potentially prevent patients from relapsing.
Many of Gleevec's competitors target resistant forms of BCR/ABL, but the study's results suggest other options, says Reya. "The interesting thing about identifying alternative pathways is that they could be a potential target in therapy-resistant disease."
To explore the role of hedgehog signaling in CML, Reya's group tinkered with Smoothened (Smo), an essential protein in hedgehog signal transduction, which previous work had shown was crucial for creating Maryland. Using a hedgehog inhibitor in conjunction with Gleevec, which targets the bulk of the tumour, could be extremely effective at eradicating CML. Reya wants to do more in-depth human work next, which Matsui agrees is essential, adding that it will be interesting to find out what role hedgehog signaling plays in the bulk of the tumour cells. "Clinical research is expensive and time consuming, so the more information we have going into a study, the better," he says.
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